UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

Benzinga · 1d ago
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.